Literature DB >> 22468098

Iron overload during follow-up after tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma.

Soo Jin Bae1, Christine Kang, Ki Woong Sung, Hee Won Chueh, Meong Hi Son, Soo Hyun Lee, Keon Hee Yoo, Hong Hoe Koo.   

Abstract

Multiple RBC transfusions inevitably lead to a state of iron overload before and after high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT). Nonetheless, iron status during post-SCT follow-up remains unknown. Therefore, we investigated post-SCT ferritin levels, factors contributing to its sustained levels, and organ functions affected by iron overload in 49 children with high-risk neuroblastoma who underwent tandem HDCT/autoSCT. Although serum ferritin levels gradually decreased during post-SCT follow-up, 47.7% of the patients maintained ferritin levels above 1,000 ng/mL at 1 yr after the second HDCT/autoSCT. These patients had higher serum creatinine (0.62 vs 0.47 mg/mL, P = 0.007) than their counterparts (< 1,000 ng/mL). Post-SCT transfusion amount corresponded to increased ferritin levels at 1 yr after the second HDCT/autoSCT (P < 0.001). A lower CD34(+) cell count was associated with a greater need of RBC transfusion, which in turn led to a higher serum ferritin level at 1 yr after HDCT/autoSCT. The number of CD34(+) cells transplanted was an independent factor for ferritin levels at 1 yr after the second HDCT/autoSCT (P = 0.019). Consequently, CD34(+) cells should be transplanted as many as possible to prevent the sustained iron overload after tandem HDCT/autoSCT and consequent adverse effects.

Entities:  

Keywords:  Autologous Stem Cell Transplantation; Deferasirox; High-Dose Chemotherapy; Iron Chelation Treatment; Iron Overload; Neuroblastoma

Mesh:

Substances:

Year:  2012        PMID: 22468098      PMCID: PMC3314847          DOI: 10.3346/jkms.2012.27.4.363

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  20 in total

1.  Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors.

Authors:  Hee Won Chueh; Ki Woong Sung; Soo Hyun Lee; Keon Hee Yoo; Hong Hoe Koo; Ju Youn Kim; Eun Joo Cho
Journal:  Pediatr Blood Cancer       Date:  2011-06-02       Impact factor: 3.167

Review 2.  Free radicals, antioxidants, and human disease: where are we now?

Authors:  B Halliwell; J M Gutteridge; C E Cross
Journal:  J Lab Clin Med       Date:  1992-06

3.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

Authors:  Luca Malcovati; Matteo Giovanni Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Marina Boni; Erica Travaglino; Francesco Passamonti; Luca Arcaini; Margherita Maffioli; Paolo Bernasconi; Mario Lazzarino; Mario Cazzola
Journal:  J Clin Oncol       Date:  2005-09-26       Impact factor: 44.544

4.  Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy.

Authors:  P Harmatz; E Butensky; K Quirolo; R Williams; L Ferrell; T Moyer; D Golden; L Neumayr; E Vichinsky
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

5.  A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

Authors:  Maria Domenica Cappellini; Alan Cohen; Antonio Piga; Mohamed Bejaoui; Silverio Perrotta; Leyla Agaoglu; Yesim Aydinok; Antonis Kattamis; Yurdanur Kilinc; John Porter; Marcello Capra; Renzo Galanello; Slaheddine Fattoum; Guillermo Drelichman; Carmelo Magnano; Monica Verissimo; Miranda Athanassiou-Metaxa; Patricia Giardina; Alexandra Kourakli-Symeonidis; Gritta Janka-Schaub; Thomas Coates; Christiane Vermylen; Nancy Olivieri; Isabelle Thuret; Herbert Opitz; Catherine Ressayre-Djaffer; Peter Marks; Daniele Alberti
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

6.  Presence of iron catalytic for free radical reactions in patients undergoing chemotherapy: implications for therapeutic management.

Authors:  T C Carmine; P Evans; G Bruchelt; R Evans; R Handgretinger; D Niethammer; B Halliwell
Journal:  Cancer Lett       Date:  1995-08-01       Impact factor: 8.679

7.  Iron overload in bone marrow transplant recipients.

Authors:  S I Strasser; K V Kowdley; G E Sale; G B McDonald
Journal:  Bone Marrow Transplant       Date:  1998-07       Impact factor: 5.483

8.  Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia.

Authors:  N M Butt; R E Clark
Journal:  Bone Marrow Transplant       Date:  2003-11       Impact factor: 5.483

9.  Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation.

Authors:  A Altès; A F Remacha; A Sureda; R Martino; J Briones; C Canals; S Brunet; J Sierra; E Gimferrer
Journal:  Bone Marrow Transplant       Date:  2002-06       Impact factor: 5.483

10.  Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias.

Authors:  Peter D Jensen; Finn T Jensen; Thorkil Christensen; Johan L Nielsen; Joergen Ellegaard
Journal:  Blood       Date:  2002-08-22       Impact factor: 22.113

View more
  1 in total

1.  Hematologic recovery after tandem high-dose chemotherapy and autologous stem cell transplantation in children with high-risk solid tumors.

Authors:  Meong Hi Son; Dong Hwan Kim; Soo Hyun Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Ju Youn Kim; Eun Joo Cho; Eun Suk Kang; Dae Won Kim
Journal:  J Korean Med Sci       Date:  2013-01-29       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.